

Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer

Information for the public

Published: 26 July 2023

www.nice.org.uk

Selpercatinib (Retsevmo) is available with [managed access](#). It is a possible treatment for untreated RET fusion-positive advanced non-small-cell lung cancer in adults.

More evidence on selpercatinib is being collected. After this, NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available with managed access until then.

If you are not eligible for selpercatinib but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on lung cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Roy Castle Lung Foundation](#), 0333 323 7200
- [Lung Cancer Nursing UK \(LCNUK\)](#), 01675 477 607
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5289-2